CN117398398A - 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 - Google Patents

包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 Download PDF

Info

Publication number
CN117398398A
CN117398398A CN202311312855.3A CN202311312855A CN117398398A CN 117398398 A CN117398398 A CN 117398398A CN 202311312855 A CN202311312855 A CN 202311312855A CN 117398398 A CN117398398 A CN 117398398A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
hours
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311312855.3A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯多佛·J·伯恩斯
丹尼尔·C·佩维尔
路易吉·谢里
蒂莫西·亨克尔
丹尼尔·麦加里
劳伦斯·罗森
格拉尔德·布伦纳
吉恩·巴普蒂斯特·阿林
安娜·费尔南德斯卡萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunding Xinyao Singapore Ltd
Original Assignee
Yunding Xinyao Singapore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunding Xinyao Singapore Ltd filed Critical Yunding Xinyao Singapore Ltd
Publication of CN117398398A publication Critical patent/CN117398398A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
CN202311312855.3A 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 Pending CN117398398A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762467750P 2017-03-06 2017-03-06
US201762467752P 2017-03-06 2017-03-06
US62/467,752 2017-03-06
US62/467,750 2017-03-06
US201762564990P 2017-09-28 2017-09-28
US201762564989P 2017-09-28 2017-09-28
US62/564,989 2017-09-28
US62/564,990 2017-09-28
CN201880030083.5A CN110678186A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
PCT/US2018/020968 WO2018165048A1 (en) 2017-03-06 2018-03-05 Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880030083.5A Division CN110678186A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Publications (1)

Publication Number Publication Date
CN117398398A true CN117398398A (zh) 2024-01-16

Family

ID=63448038

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311312855.3A Pending CN117398398A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN201880030083.5A Pending CN110678186A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880030083.5A Pending CN110678186A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Country Status (17)

Country Link
US (4) US11091505B2 (enExample)
EP (1) EP3592362B1 (enExample)
JP (2) JP7634934B2 (enExample)
KR (1) KR102603489B1 (enExample)
CN (2) CN117398398A (enExample)
AU (1) AU2018230991B2 (enExample)
BR (1) BR112019018447A2 (enExample)
CA (1) CA3055253A1 (enExample)
ES (1) ES3015371T3 (enExample)
HR (1) HRP20250459T1 (enExample)
IL (2) IL268981B2 (enExample)
MA (1) MA47743A (enExample)
MY (1) MY196966A (enExample)
PH (1) PH12019502037B1 (enExample)
PL (1) PL3592362T3 (enExample)
SG (1) SG11201908181XA (enExample)
WO (1) WO2018165048A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CN1910161A (zh) 2004-01-26 2007-02-07 默克公司 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型
SG10201600029PA (en) 2004-03-30 2016-02-26 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
CN1965838A (zh) * 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
BRPI0820531A2 (pt) 2007-11-13 2012-07-10 Protez Pharmaceuticals Inc inibidores de beta-lactamase
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
KR101738210B1 (ko) * 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) * 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) * 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
KR101935186B1 (ko) 2014-09-04 2019-01-03 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류를 함유하는 제제
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020056048A1 (en) 2018-09-12 2020-03-19 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
TWI846759B (zh) 2018-11-29 2024-07-01 美商維納拓爾斯製藥公司 包含β-內醯胺酶抑制劑的組合物及其用途

Also Published As

Publication number Publication date
CN110678186A (zh) 2020-01-10
US12187752B2 (en) 2025-01-07
PH12019502037B1 (en) 2024-06-05
BR112019018447A2 (pt) 2020-04-14
EP3592362A1 (en) 2020-01-15
KR20190117790A (ko) 2019-10-16
IL268981A (en) 2019-10-31
JP7634934B2 (ja) 2025-02-25
HRP20250459T1 (hr) 2025-06-06
JP2023061946A (ja) 2023-05-02
EP3592362A4 (en) 2020-09-02
EP3592362C0 (en) 2025-02-19
IL268981B2 (en) 2023-09-01
WO2018165048A1 (en) 2018-09-13
US20220002322A1 (en) 2022-01-06
MA47743A (fr) 2020-01-15
US11091505B2 (en) 2021-08-17
US11820784B2 (en) 2023-11-21
JP2020510661A (ja) 2020-04-09
MY196966A (en) 2023-05-15
IL301591B1 (en) 2025-11-01
KR102603489B1 (ko) 2023-11-16
SG11201908181XA (en) 2019-10-30
AU2018230991B2 (en) 2023-07-13
US20200010485A1 (en) 2020-01-09
US20240101580A1 (en) 2024-03-28
EP3592362B1 (en) 2025-02-19
ES3015371T3 (en) 2025-05-05
IL268981B1 (en) 2023-05-01
US20250320235A1 (en) 2025-10-16
AU2018230991A1 (en) 2019-09-19
PL3592362T3 (pl) 2025-06-23
CA3055253A1 (en) 2018-09-13
PH12019502037A1 (en) 2020-03-09
IL301591A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
US12187752B2 (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3292123B1 (en) Solid forms of a compound modulating kinases
TWI788702B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
US20160046603A1 (en) Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(6-Amino-3,5-Difluoropyridine-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7-(3-Hydroxyazetidin-1-Yl)-4-Oxo-3-Quinolinecarboxylate
CN104211708A (zh) 苯并噁嗪酮衍生物及其作为抗菌剂的应用
CN111971272A (zh) 柳氮磺吡啶盐组合物及其使用方法
HK40013654A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
RU2515557C1 (ru) Фармацевтическая соль 8-метил-7-[5-метил-6-(метиламино)-3-пиридинил]-1-циклопропил-4-оксо-1,4-дигидро-3-хинолинкарбоновой кислоты, ее содержащая фармацевтическая композиция, лекарственное средство и способ лечения или профилактики бактериальных инфекций с помощью вышеуказанной соли
CN102770416B (zh) 美他沙酮共晶体
EA048377B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
TW201444558A (zh) 使用喹諾酮類抗生素治療淋病感染的方法
EA042812B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
HK40020554B (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
HK40020554A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN120230121A (zh) 苯并噁嗪噁唑烷酮类化合物otb-658的晶型i及其制备方法和其组合物与用途
WO2025032190A1 (en) Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl
HK1248223B (en) Solid forms of a compound modulating kinases
HK1248223A1 (en) Solid forms of a compound modulating kinases
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097446

Country of ref document: HK